High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Lifespan Health and Aging
Other featured articles
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?
This study provides the first evidence to our knowledge that near-universal access to Medicare at age 65 is associated with improvements in population-level cancer mortality, and provides new evidence on the differences in the impact of health insurance by gender.
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
Between 1995 and 2012, price per median survival gain increased, a finding consistent with existing literature, but price per mean survival gain increased at a considerably slower rate.
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
About this section
People are living longer, which brings obvious benefits as well as considerable challenges — from Alzheimer’s and other age-related diseases to increased injuries, disabilities and poverty risks. Policymakers around the world rely on Schaeffer Center research and modeling tools for finding ways to help keep people as healthy as possible throughout their lives.